Modality
mAb (humanized IgG1)
Mechanism
IL-23 p19 subunit inhibitor
Targets
IL-23 (p19)
Storage
refrigerated 2–8 °C (RT excursion up to 24 h)
Approved
plaque psoriasis — FDA 2019 · psoriatic arthritis — FDA 2022
In trial
hidradenitis suppurativa
Monitoring
TB pre-treatment
Last verified
2026-04-14
Mechanism of action
Skyrizi label (FDA, 2024)drugtargetsignalingeffectorcellularphenotype⊣ red bar = blocked/reduced by drug
Monitoring & workup
Baseline workup
- •TB IGRA (or PPD)
- •HBV sAg if high risk; HCV Ab if high risk
- •Update age-appropriate vaccines before start
Ongoing monitoring
- •No routine labs
- •Annual TB screening if high exposure risk
- •IL-17 class: monitor for candida overgrowth + IBD flare
- •IL-23 class: monitor for injection-site reactions